Evidence map›Paper›PMID 36622700›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.

Shernan G Holtan, Constanza Savid-Frontera, Kelly Walton, Anne A Eaton, Connor Demorest, Andrea Hoeschen, Ling Zhang, Kayla Reid, Tony Kurian, Zena Sayegh and 11 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Shernan G Holtan *Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-5054-9419
Constanza Savid-Frontera *Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0001-8614-3528
Kelly Walton *Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-9780-9401
Anne A EatonDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-5900-9745
Connor DemorestDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-3054-6288
Andrea HoeschenDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-6920-1183
Ling ZhangDepartment of Hematopathology and Laboratory Medicine, Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-1463-1458
Kayla ReidDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-6585-0781
Tony KurianDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0001-5847-0468
Zena SayeghDepartment of Hematopathology and Laboratory Medicine, Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-2722-8510
Estefania JuliaDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-7481-8994
Joseph MaakaronDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-1732-6694
Veronika BachanovaDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-9325-432X
Najla El JurdiDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-9268-9655
Margaret L MacMillanDivision of Pediatric Blood and Marrow Transplantation & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-0755-0852
Daniel J WeisdorfDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-8078-8579
Martin FelicesDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-5945-0634
Jeffrey S MillerDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-0339-4944
Bruce R BlazarDivision of Pediatric Blood and Marrow Transplantation & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-9608-9841
Marco L Davila *Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-6270-3065
Brian C Betts *Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-7643-2422
University of Minnesota Medical Center · USMoffitt Cancer Center · USUniversity of Minnesota · US

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5M
Single Cell Analysis and ImmunogeneticsP01HL158505 · NHLBI · DANA-FARBER CANCER INST · PI Corey S Cutler · 2022 to 2026
$15.3M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory DiseaseR01HL155114 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, NOELLE, RANDOLPH J. · 2021 to 2024
$2.7M
NCI NIH HHS P01 CA065493NHLBI NIH HHS P01 HL158505NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL147324NHLBI NIH HHS R01 HL155114NIAID NIH HHS P01 AI056299NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

purposeAcute and chronic GVHD remain major causes of transplant-related morbidity and mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). We have shown CD83 chimeric antigen receptor (CAR) T cells prevent GVHD and kill myeloid leukemia cell lines. In this pilot study, we investigate CD83 expression on GVHD effector cells, correlate these discoveries with clinical outcomes, and evaluate critical therapeutic implications for transplant recipients. EXPERIMENTAL

designCD83 expression was evaluated among circulating CD4+ T cells, B-cell subsets, T follicular helper (Tfh) cells, and monocytes from patients with/without acute or chronic GVHD (n = 48 for each group), respectively. CD83 expression was correlated with survival, TRM, and relapse after alloHCT. Differential effects of GVHD therapies on CD83 expression was determined.

resultsCD83 overexpression on CD4+ T cells correlates with reduced survival and increased TRM. Increased CD83+ B cells and Tfh cells, but not monocytes, are associated with poor posttransplant survival. CD83 CAR T eliminate autoreactive CD83+ B cells isolated from patients with chronic GVHD, without B-cell aplasia as observed with CD19 CAR T. We demonstrate robust CD83 antigen density on human acute myeloid leukemia (AML), and confirm potent antileukemic activity of CD83 CAR T in vivo, without observed myeloablation.

conclusionsCD83 is a promising diagnostic marker of GVHD and warrants further investigation as a therapeutic target of both GVHD and AML relapse after alloHCT.

Indexed as

Bronchiolitis Obliterans SyndromeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteReceptors, Chimeric AntigenADP-ribosyl Cyclase 1HumansMembrane GlycoproteinsPilot ProjectsRecurrenceTransplantation, HomologousADP-ribosyl Cyclase 1CD38 protein, humanMembrane GlycoproteinsReceptors, Chimeric Antigen

Identifiers

PMID36622700
PMCPMC10011883
OpenAlexW4313877296

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.